Pfizer, manufacturing

Pfizer's CEO says he's got a plan to deal with Trump's tariffs — move overseas drug manufacturing to the US
"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's election victory.
Pfizer could use existing US manufacturing to counter potential tariff hit
By Christy Santhosh (Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required, as the Trump administration threatens numerous tariffs on imported goods.
Pfizer could use existing U.S. production to counter tariff hit, Reuters reports
Pfizer (PFE) may move overseas manufacturing to its existing plants in the U.S., if required, as the Trump administration threatens numerous
Pfizer Prepared to Reshore Manufacturing if Trump Makes Good on Tariff Threats
Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing facilities across the U.S. in five years.
Pfizer could shift overseas production to US if Trump's pharma tariffs take hold, CEO says
As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if pharmaceut | Pfizer’s local manufacturing setup is already well positioned in the U.
Pfizer may soon move its overseas manufacturing to United States to counter potential tariff hit
Pfizer CEO Albert Bourla on Monday said that the company might move overseas manufacturing to its existing plants in the United States. The plan comes as the Trump administration
Pfizer's Strategic Manufacturing Shift Amidst Tariff Threats
Pfizer CEO Albert Bourla announced the possibility of shifting overseas manufacturing to U.S. plants. This response is due to the Trump administration's tariff threats on imported goods. Bourla mentioned their U.
Pfizer could move outside manufacturing to the US, says CEO
(Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the U.S., if required, as the Donald Trump administration threatens numerous tariffs on imported goods.
STAT5h
Questions about Pfizer’s GenAI ‘Health Answers’
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...
Pfizer Remains A Good Pick For Dividend Investors
Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...
FiercePharma11d
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
STAT6h
Pharmalittle: We’re reading about Pfizer navigating tariffs, Makary’s pledge to avoid conflicts, and more
Pfizer CEO Albert Bourla said the drugmaker might move overseas manufacturing to its plants in the U.S. as Trump threatens ...
Trump Introducing Pfizer CEO Sparks Loud Booing Inside White House
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
Pfizer comments on Q1, Q2 numbers amid higher rebate expense
Says “I don’t think the Street” has adjusted yet and that “they should have a look on it.” The company says the rebates that Pfizer (PFE) will ...
Pfizer Inc. stock rises Friday, still underperforms market
Shares of Pfizer Inc. PFE advanced 1.26% to $26.43 Friday, on what proved to be an all-around favorable trading session for ...
Hosted on MSN1d
Pfizer says more drugs can be made in its US plants for domestic market, if needed
Pfizer CEO Albert Bourla said on Monday that the drugmaker can shift manufacturing for the US market to its existing plants in the US, as the threat of tariffs puts a question mark over global supply ...